
Advantages of Cas9 mRNA for Gene Editing: Precision, Control & Cost Effective
CRISPR-Cas9 RNA-DNA complex. Structure of Cas9 endonuclease (yellow-orange) complexed with a guide RNA (blue), a target DNA (pink) and a non-target DNA (green). The revolutionary CRISPR-Cas gene editing technology has unlocked unprecedented possibilities in genome engineering, gene therapy, and cell therapy. The choice between using Cas9 mRNA or Cas9 protein becomes crucial. One has to…

Vernal Announces Successful Multigram mRNA Scale-up at the New GMP Facility
Vernal has successfully demonstrated its ability to manufacture high quality mRNA using CGMP-compliant platform. We now offer the first integrated platform for CGMP production of MCB, pDNA, mRNA, and LNP at our GMP facility. Contact us today to reserve your GMP manufacturing slot.

June Newsletter
Vernal had a great experience at BIO this week and we hope we were able to catch you in Boston. If not, take a quick read on Vernal updates and let us know how we can support your mRNA needs!

Revolutionizing Medicine: How mRNA Technology Engineers Next-Generation Antibodies
By Christian Cobaugh, CEO and Founder Monoclonal antibodies (mAbs) have emerged as one of the most successful drug products and biochemical reagents of the 21st century, owing to their broad range of activities, target specificity, and ease of manufacturing. There are now several successful platforms available to discover and engineer novel antibodies with desirable drug-like…

April Newsletter
We cannot believe it has been 2 years. Happy Birthday Vernal Biosciences! See how Vernal has grown since 2021 and expanded its capabilities for mRNA, LNP, and GMP!

Vernal’s World Vaccine Congress Poster
Sorry we missed you at the World Vaccine Congress in DC this April (2023). As previously mentioned, we showcased our poster providing information on the efficacy of LNP-mRNA using Sars-Cov-2 spike protein to demonstrate. We encourage you to download our poster here and see the data. Feel free to contact us at [email protected] for further…